Lymphoma, Metastatic Cancer, Solid Tumor
Conditions
Keywords
Locally advanced/unresectable, Metastatic solid tumor, Lymphoma, Anti-PD-1, PD-1, PD1, Anti-LAG-3, LAG-3, LAG3, Anti-TIM-3, TIM-3, TIM3
Brief summary
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Detailed description
Part 1 of this study will evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) to establish the maximum tolerated dose (MTD) and/or the selected dose of sequential escalating doses of Sym021 when administered once every 2 weeks (Q2W) by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available Part 2 of the study will evaluate the safety, tolerability, and DLTs to establish the MTD and/or the selected dose of sequential escalating doses of Sym022 when administered Q2W in combination with a fixed dose of 3 mg/kg of Sym021, each by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available Part 3 of the study will evaluate of the safety, tolerability, and DLTs to establish the MTD and/or the selected dose of sequential escalating doses of Sym023 when administered Q2W in combination with fixed doses of 3 mg/kg of Sym021 and either 1, 3 or 5 mg/kg of Sym022, each by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Interventions
DRUGSym021
Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
DRUGSym022
Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
DRUGSym023
Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Sponsors
Symphogen A/S
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients, ≥ 18 years of age at the time of obtaining informed consent. * Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphoma. * Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor. * Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit. * Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. * Persons of childbearing potential agreeing to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug(s); men agreeing to refrain from sperm donation during this period.
Exclusion criteria
* Women who are pregnant or intending to become pregnant before, during, or within 6 months after the last dose of study drug; women who are breastfeeding; persons of childbearing potential and not willing to use a highly effective method of contraception. * Central nervous system (CNS) malignancies; patients with known, untreated CNS or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required. * Hematologic malignancies other than lymphoma. * Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable. * Active uncontrolled bleeding or a known bleeding diathesis. * Clinically significant cardiovascular disease or condition. * Significant ocular disease or condition, including history of an autoimmune or inflammatory disorder. * Significant pulmonary disease or condition. * Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition. * An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive medications. * History of organ transplantation (e.g., stem cell or solid organ transplant). * History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy. * Patients with unresolved \> Grade 1 toxicity associated with any prior antineoplastic therapy except for persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, lymphopenia, hypomagnesemia, and/or end-organ failure being adequately managed by hormone replacement therapy. * Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1. * Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). Drugs and Other Treatments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria. | 12 months | Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 or Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. |
| Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria. | 12 months | Assess the safety and tolerability of Sym021 monotherapy on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. |
| Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria. | 12 months | Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 and Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the concentration-time curve in a dosing interval (AUC) | 24 months | Will be estimated using non-compartmental methods and actual timepoints. |
| Maximum concentration (Cmax) | 24 months | Will be derived from observed data. |
| Time to reach maximum concentration (Tmax) | 24 months | Will be derived from observed data. |
| Evaluation of the immunogenicity of Sym021 as a single agent and in combination with Sym022 and Sym023. | 24 months | Serum sampling to assess the potential for anti-drug antibody (ADA) formation. |
| Terminal elimination half-life (T½) | 24 months | Will be estimated using non-compartmental methods and actual timepoints. |
| Clearance (CL) | 24 months | Will be estimated using non-compartmental methods and actual timepoints. |
| Trough concentration (Ctrough) | 24 months | Will be derived from observed data. |
| Evaluation of objective response (OR) or stable disease (SD). | 24 months | Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017), or Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST), depending on tumor type. |
| Time to progression (TTP) of disease. | 24 months | Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. |
Countries
Canada, United States
Outcome results
None listed